Pemazyre™ (pemigatinib) is the first and only US Food and Drug Administration (FDA)-approved kinase inhibitor indicated for the treatment of cholangiocarcinoma.
Pemazyre was developed by Incyte Corporation, which granted rights to Innovent Biologics for the development and commercialisation of the drug in haematology and oncology in countries including Macau, Hong Kong, Taiwan and Mainland China.
Incyte holds all other rights for the development and commercialisation of pemigatinib outside of the US.
Pemazyre (pemigatinib) is the first targeted treatment for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma. It was authorised under accelerated approval on the basis of overall response rate and duration of response (DOR).
Pemazyre (pemigatinib) is available as oral tablets with a recommended dosage of 13.5mg once a day for 14 consecutive days.